Orthotopic liver retransplantation (re-OLT) is highly controversial. The objectives of this study were to determine the validity of a recently developed United Network for Organ Sharing (UNOS) multivariate model using an independent cohort of patients undergoing re-OLT outside the United States, to determine whether incorporation of other variables that were incomplete in the UNOS registry would provide additional prognostic information, to develop new models combining data sets from both cohorts, and to evaluate the validity of the model for end-stage liver disease (MELD) in patients undergoing re-OLT. Two hundred eighty-one adult patients undergoing re-OLT (between 1986 and 1999) at 6 foreign transplant centers comprised the validation cohort. We found good agreement between actual survival and predicted survival in the validation cohort; 1-year patient survival rates in the low-, intermediate-, and high-risk groups (as assigned by the original UNOS model) were 72%, 68%, and 36%, respectively (P < .0001). In the patients for whom the international normalized ratio (INR) of prothrombin time was available, MELD correlated with outcome following re-OLT; the median MELD scores for patients surviving at least 90 days compared with those dying within 90 days were 20.75 versus 25.9, respectively (P ‫؍‬ .004). Utilizing both patient cohorts (n ‫؍‬ 979), a new model, based on recipient age, total serum bilirubin, creatinine, and interval to re-OLT, was constructed (whole model 2 ‫؍‬ 105, P < .0001). Using the c-statistic with 30-day, 90-day, 1-year, and 3-year mortality as the end points, the area under the receiver operating characteristic (ROC) curves for 4 different models were compared. In conclusion, prospective validation and use of these models as adjuncts to clinical decision making in the management of patients being considered for re-OLT are warranted. (HEPATOLOGY 2003;38:460-469.) 
T he growing discrepancy between the static number of donor organs and the growing number of potential orthotopic liver transplantation (OLT) recipients has led to dramatic increases in the number of patients waiting for OLT, as well as deaths while on the waiting list. 1 Advances in surgical and medical care of recipients have significantly improved patient and graft survival. 2 However, despite such progress, recurrence of liver disease can occur for virtually all primary indications of OLT, and a subset of these patients develop allograft failure. 3 A steady increase in the number of OLT patients surviving long term has resulted in an increasing population of primary OLT patients who may ultimately require additional grafts. Therefore, although orthotopic liver retransplantation (re-OLT) currently accounts for approximately 10% of all liver transplantations, 4 the proportion of patients requiring re-OLT is expected to grow as primary transplant patients survive long enough to develop graft failure caused by recurrent disease. Indeed, one model has predicted that the number of re-OLT candidates may eventually outstrip the number of potential donor livers. 5 We recently developed a prognostic model based on data collected from the United Network for Organ Sharing (UNOS) registry to predict survival following re-OLT. 6 Following analysis of 16 donor and recipient factors, a 5-variable model with specific risk scores for individual patients was derived. However, we recognize the inherent limitations of registry data, e.g., missing, incomplete, or inaccurate data. The goals of the current analysis were to determine the applicability of this UNOS model on an independent, heterogeneous cohort of patients, i.e., patients undergoing re-OLT at transplantation programs outside the United States. We also sought to determine whether other variables that were incomplete in the UNOS registry database (e.g., specific etiologies of graft failure) might contribute to the estimation of prognosis. Moreover, in the patients undergoing re-OLT for whom the international normalized ratio (INR) of prothrombin time was available, we tested the predictive ability of the model for end-stage liver disease (MELD), 7 originally developed to assess the short-term prognosis of patients with cirrhosis. Finally, because of the recent adoption of a new system to allocate livers and because of the ethical obligation to offer re-OLT to patients with early graft failure (within 2 weeks of primary transplantation), we developed new models based on these considerations and combining data from the UNOS and international cohorts. Using the c-statistic with 30-day, 90-day, 1-year, and 3-year mortality as end points, the area under the receiver operating characteristic (ROC) curve for 4 different survival models were compared.
Patients and Methods
Patient Population and Data Collection. The study population consisted of 281 patients who underwent re-OLT for hepatic allograft failure between April 4, 1986, and January 22, 1999, at 6 centers. The centers included Virchow Klinikum, Berlin, Germany (n ϭ 74); King's College Hospital, London, United Kingdom (n ϭ 74); Hospital La Fe, Valencia, Spain (n ϭ 22); Unidad de Trasplante Hepático, Ciudad Sanitaria y Universitaria de Bellvitge, Barcelona, Spain (n ϭ 58); Hospital Puerta de Hierro, Universidad Autonoma, Madrid, Spain (n ϭ 30); and University of Queensland Hospital, Brisbane, Australia (n ϭ 23). Each liver transplantation program contributed demographic, clinical, histologic, and survival data on consecutive patients undergoing liver retransplantation at their centers.
The UNOS cohort has been described previously in detail. 6 Briefly, this cohort was comprised of 1,356 patients who had undergone re-OLT in the United States between 1990 and 1996. UNOS status (as used between 1990 and November 1994) had been designated as follows: 1 (intensive care unit bound with a life expectancy of less than 7 days without transplant), 2 (continuous hospitalization of at least 5 days), and 3 (continuous medical care).
Statistical Methodology. As previously described in detail, 6 the starting time for all survival analyses was the date of re-OLT, and death from any cause was treated as a failure for survival analyses. Data for each patient were entered into the Cox proportional hazards regression model 8, 9 in which each patient is assigned a risk score (R): For time-dependent analysis, the Kaplan-Meier product-limit estimate was used with comparison between risk groups performed via the log-rank test. Data from both UNOS and international cohorts were combined to generate a new model using Cox proportional hazards for time-dependent analysis and logistic regression analysis for binary outcomes.
The JMP 4.04 and SAS 6.12 (SAS Institute Inc, Cary, NC) statistical packages were used. Unpaired t test (for comparison of 2 groups) and 1-way analysis of variance (for comparison of more than 2 groups) were used for parametric data, and Wilcoxon rank sum and KruskallWallis test were used for nonparametric data. For categorical data, the Mantel-Haenszel 2 test was used for statistical comparison of means (ϮSEM) and proportions between groups, respectively. A P value less than .05 was considered significant for all situations. To assess the ability of the mathematic models to correctly stratify patients according to risk of death at different time points, the concordance (c-statistic) equivalent to the area under the (ROC) curve was measured. 10 By convention, a c-statistic of 0.7 or greater is considered to be clinically useful.
Results
International Patients. Table 1 shows the baseline demographic, clinical, and biochemical characteristics of the patients undergoing re-OLT at the 6 non-U.S. transplantation programs and from the UNOS registry that contributed data to this analysis. The average age was 43.5 years, the median interval to re-OLT following primary OLT was 121 days, and the median length of follow-up to date of death or last follow-up was 1.5 years (longest, 11.8 years); 144 (51.2%) patients received tacrolimus as their main immunosuppressive medication, and 132 (47%) received cyclosporine. Alcohol-and HCV-related liver disease accounted for the most common indications for primary transplantation (Fig. 1A) . Underlying indications for primary transplantation and specific etiologies of graft failure (Fig. 1B) did not impact survival following retransplantation ( Fig. 2 and data not shown) .
Approximately one fourth of patients undergoing re-OLT in the validation cohort were HCV positive, including 9 patients who had undergone primary transplantation for hepatocellular carcinoma and 3 patients coinfected with hepatitis B. Figure 3 shows Kaplan-Meier survival analysis for the subset of patients who were HCV seropositive and underwent re-OLT for graft failure related solely to HCV (n ϭ 19), HCV-seropositive patients who underwent OLT for causes other than HCV-related . Kaplan-Meier analysis for patients undergoing retransplantation according to HCV status: HCV-infected recipients undergoing retransplantation for HCV-related graft failure ("HCV alone," n ϭ 19), HCVnegative recipients undergoing retransplantation (n ϭ 187), and HCVinfected recipients undergoing retransplantation for causes other than recurrent HCV ("HCV other," n ϭ 51). Patients undergoing transplantation prior to 1990 (HCV antibody testing) were excluded. Inset: KaplanMeier analysis for the same cohort based solely on HCV status (negative/ positive). P ϭ NS for all analyses.
graft failure (n ϭ 51; including 16 patients with hepatic artery thrombosis, 17 with primary nonfunction (PNF) and 7 with chronic rejection), and the HCV-seronegative group (n ϭ 187; patients undergoing transplantation prior to the availability of HCV antibody testing in 1990 were excluded). There were no statistically significant differences among the 3 groups with regard to gender, serum bilirubin, serum creatinine, original UNOS model risk score (mean 0.89, 0.90, and 0.91, respectively), or MELD score (mean 21, 24, 24.6, respectively). However, patients undergoing retransplantation for HCV alone were significantly older (mean age, 50.6 years vs. 48.3 years in the HCV with other causes of graft failure group and 42.3 years in the HCV-negative group, P Ͻ .0003) and underwent retransplantation at a significantly greater time interval (1,079.5 days after primary transplant vs. 182 and 411 days, respectively, P Ͻ .0001). These results are in accord with recent studies demonstrating that cumulative patient survival after re-OLT is not significantly affected by HCV status 11 ; moreover, inclusion of HCV status did not increase the predictive value of the original UNOS model. 6 Validation of Original UNOS Model With International Cohort. The cohort of patients undergoing retransplantation at non-U.S. programs differed significantly from the UNOS cohort previously used to develop the original survival model (Table 1) . Specifically, the UNOS patients were older (mean, 46.3 vs. 43.5 years, respectively; P ϭ .0003), had higher median serum creatinine levels (1.9 vs. 1.47 mg/dL, respectively; P Ͻ .0001), and a much greater proportion were listed as UNOS status 1 at the time of regrafting (60.1% vs. 32%, respectively; P Ͻ .0001). We tested the validity of the original UNOS model in this independent population of patients by combining the values of the 5 prognostic variables as follows:
Rϭ.024 (recipient age in years)
ϩ.112(͌bilirubin in mg/dL) ϩ.230(log e creatinine mg/dL) Ϫ.974 (cause of graft failure)ϩUNOS coefficient, with the cause of graft failure coded as 1 for PNF and zero for non-PNF; for UNOS status 1, the coefficient is equal to Ϫ.261; for status 2, Ϫ.463; for status 3, Ϫ1.07. Risk scores were calculated for each patient in the international cohort. As shown in Fig. 4 , the previously described riskscore cutoffs successfully stratified patients undergoing re-OLT outside the United States, although the survival curves for the low-and intermediate-risk groups were closer than in the UNOS population. As predicted, patients with a risk score Ն1.47 had extremely poor survival, i.e., 36% survival at 1 year in the international cohort (41% in the UNOS cohort). In contrast, international patients with risk scores Ͻ0.75 had a 72% 1-year survival (74% in the UNOS cohort). The intermediate-risk patients demonstrated 68% 1-year survival in the international cohort (65% in the UNOS cohort). Therefore, despite significant demographic and clinical differences between the validating international cohort and the UNOS cohort, the previously developed model is able to provide clear-cut discrimination of patients with low versus high risk of mortality following re-OLT. In addition, subgroup analyses limited to patients undergoing retrans- Analysis of MELD for Predicting Survival Following Retransplantation. The MELD 7 is used to stratify patients for prioritization for OLT 12 and has been recently shown to predict mortality after primary transplantation. 13 The MELD utilizes 3 variables, bilirubin, creatinine, and INR, to generate a risk score; therefore, it shares 2 variables with the original UNOS model found to be predictive of survival following re-OLT. INR levels were available for 135 of the patients undergoing re-OLT in the international cohort. The MELD predicted survival accurately by proportional hazards fit (P ϭ .016, 2 ϭ 5.8). The average MELD score for these patients was 24.4 Ϯ 10.06 (mean Ϯ SD) and was statistically different in patients who survived at least 90 days following re-OLT versus those who died within that interval (Fig. 5) ; the medians were also significantly different (P ϭ .004, Kruskall-Wallis tests). By convention, 1 disease severity for patients awaiting primary OLT has been stratified using cutoffs of MELD Յ10, 11 to 18, 19 to 24, and Ն25. Figure 6A shows Kaplan-Meier survival analysis following re-OLT in patients with MELD scores Յ18, 19 to 24, and Ն25 (the 2 low-risk groups are combined because there were only 7 patients with scores Յ10). Because these cutoffs were derived for patients awaiting primary OLT and because the difference in patient survival within the first 90 days (following re-OLT) was not statistically significant between the MELD 19 to 24 and MELD Ն25 groups, we back calculated MELD cutoffs that adjusted for approximately an equal number of deaths in the first 3 months following re-OLT. Low-, intermediate-, and high-risk groups were comprised of 62 patients (17 deaths in the first 90 postoperative days), 40 patients (16 deaths), and 33 patients (18 deaths), respectively. Figure 6B shows Kaplan-Meier survival analysis following re-OLT stratified into these 3 risks groups, i.e., MELD Ͻ22, 22 to 31, and Ն32.
Development of New Models Combining Data
From Both Cohorts. Because of the recent adoption of the MELD score, which replaced the previous UNOS status classification based on Child-Turcotte-Pugh criteria, 14 we sought to develop a model that does not rely on UNOS status as a covariate. In addition, because PNF as an indication for re-OLT historically has been viewed as ethically obligated, we sought to construct a model based on patients who underwent re-OLT at least 2 weeks after their primary transplant. We also wanted to improve the generalizability of the model by combining data from U.S. and international cohorts. Therefore, data from 773 UNOS patients and 206 international patients who had undergone re-OLT 15 days or more after their primary transplantation comprised the combined cohort. Because these procedures were performed over a 12-year span, we analyzed whether the year of surgery affected survival. As shown in Fig. 7 , the 557 (57%) patients who underwent regrafting prior to 1994 had significantly diminished survival as compared with those patients undergoing retransplantation after January 1994: at 90 days and 1 year, 69% and 60% versus 74% and 66%, respectively. Furthermore, Cox multivariate hazards modeling confirmed the importance of year of re-OLT as an independent predictor of survival (risk ratio 0.73 for re-OLT after 1994 vs. before 1994, P ϭ .0005). However, because the ultimate goal was to develop a model to be used prospectively, we developed models that adjusted for the date of re-OLT as a covariate. Figure 8 shows the relative proportions of patients in the combined cohort according to time interval following primary OLT as well as their respective survivals. When examined as a continuous and categorical variable, the time point that yielded the most significant discriminant value with respect to survival was less than or greater than 60 days. Multivariate Cox regression analysis confirmed the independent significance of time interval (after primary OLT), age, serum bilirubin, and creatinine in predicting survival in this combined cohort. Table 2 shows the final model with these variables, their regression coefficients, and risk ratios (whole model 2 ϭ 105, P Ͻ .0001).
Risk scores for the final combined model were derived using the following equation: with zero for 15 to 60 days and 1 for patients undergoing retransplantation more than 60 days beyond their primary transplantation. The risk scores were normally distributed, and the risk scores correlated closely with the risk scores derived from the original UNOS model (P Ͻ .0001). New risk-score cutoff values dividing 3 risk groups (16 and 20) were chosen so that the 3 groups had approximately an equal number of deaths in the first 3 months following re-OLT. Low-, intermediate-, and high-risk groups were composed of 495 patients (90 deaths in the first 3 postoperative months), 284 patients (98 deaths), and 200 patients (92 deaths), respectively (Fig. 9) . Therefore, patients undergoing re-OLT with R scores Ͼ20.5 by this combined model had 90-day and 1-year survivals of 54% and 42%, respectively; in contrast, patients with R scores Յ16 had 90-day and 1-year survivals of 82% and 75%, respectively. The confidence intervals, even in the high-risk group, which has the fewest number of patients (and therefore the largest standard error), are reasonably narrow, suggesting that the probability estimates are clinically useful because the uncertainty is low. Furthermore, because of the concern that inclusion of age in the final combined model might be a discriminatory variable that should be avoided in determining organ allocation, we created a model exclusive of age. As shown in Table 3 , omission of age slightly modified the regression coefficients and risk ratios of the previous model. As described above, we determined new risk scores based on the number of deaths within the first 90 days and assigned risk groups corresponding to low-, intermediate-, and high-risk groups (Fig. 10) . These groups were composed of 517 patients (97 deaths in first 3 postoperative months), 271 patients (95 deaths), and 191 patients (88 deaths), respectively.
Assessment of Models' Validity With C-Statistic. Figure 11 shows the area under the receiver operating curves for the original UNOS model, MELD, the final combined model with age, and the final combined model exclusive of age. The c-statistics for the 4 models' prediction of 3-month, 9-month, 1-year, and 3-year mortality were found to be comparable. There were no statistically significant differences between the 4 models in their ability to predict survival at these time points (all P Ͼ .05).
Discussion
Emerging data have begun to define the natural history of hepatic allograft failure from different etiologies, including chronic rejection 15 and recurrent viral hepatitis. 16 Recent reports, for example, have shown that the evolution to HCV-related cirrhosis is considerably accelerated in OLT recipients when compared with immunocompetent patients. 17 In a study by Berenguer et al. from Valencia, 18 of 39 (46%) patients with HCV-related allograft cirrhosis developed at least 1 episode of decompensation within a mean follow-up of approximately 8 months, 18 substantially greater than the rate reported for patients who had not undergone transplantation. 19 Given the differential Fig. 9 . Kaplan-Meier survival according to risk groups assigned by final combined model (see Table 2 ); 95% confidence intervals are shown by dotted lines (P Ͻ .0001, log-rank test). Table 3 ); 95% confidence intervals are shown by dotted lines (P Ͻ .0001, log-rank test).
rates of progression to liver failure prior to and after OLT, models used to predict outcome in one group may not be applicable to assign risk for another group. Based on these considerations, alternative scoring systems have been specifically designed for liver retransplantation. 6, 9, [20] [21] [22] [23] [24] [25] Several aspects of the current study make it unique. This is the first study to a use a truly independent cohort to validate a mathematical model to predict survival after re-OLT. Our analysis corroborates the robustness of the original UNOS model, particularly in distinguishing between low-versus high-risk patients. To improve the generalizability of the model, we combined data from both UNOS and international cohorts and developed models for patients who underwent retransplantation at least 2 weeks after their primary transplantation. Because the study consisted of patients undergoing re-OLT at multiple sites throughout the world over a 12-year span, it is likely representative of diverse practice patterns. Adjusting for the year of retransplantation, we found that age, serum bilirubin, creatinine, and interval following primary OLT were predictive of outcome. Of particular interest, the etiology of non-PNF graft failure, including HCV recurrence, did not impact outcome after regrafting. Our models therefore appear generalizable to patient populations with graft failure of diverse etiologies and wide ranges of severity, an important consideration given the fact that certain indications for re-OLT (e.g., chronic rejection) have decreased, whereas others (e.g., recurrent HCV) have increased in the past decade. 4 Multivariate modeling limited to the patients with INR data showed that age, bilirubin, and creatinine remained stronger predictors of mortality (based on the level of significance and the likelihood ratio 2 test) than the INR. Nonetheless, we found the MELD to be predictive of survival after re-OLT, but the cutoffs assigning relative risk are different than what have been traditionally used to assign risk of mortality in patients awaiting primary OLT (Fig. 6) . One of the criticisms of the MELD and potentially any model used to determine outcomes of a complex disease process is that it lacks the precision to be a valid predictor of an individual patient's true risk of death. 26 In this regard, we found wide variations in confidence limits for the projected survival with a given range of MELD scores ( Fig. 6A and 6B ). Whether this large standard error is a reflection of the relatively small number of patients for whom INR was available (n ϭ 135) or whether the MELD needs further refinement for patients undergoing re-OLT requires investigation. By analyzing data from almost 1,000 patients undergoing re-OLT, we derived new models (exclusive of INR) and defined relatively tight confidence limits (Figs. 9 and 10 ).
Survival following primary or secondary transplantation has been shown to diminish as level of urgency increases. 4, 23 Numerous authors have argued that, in the face of poor outcome and limited resources, the duty to manage the most urgently ill patients should be balanced against the duty to allocate scarce resources to those who are most likely to benefit from them. 27 Thus, an allocation system attuned to efficacy concerns might give priority to a transplantation candidate who has a high posttransplantation survival rate (less urgency) as opposed to a higher pretransplantation mortality. 4 Citing these efficacy concerns, the curtailment of re-OLT has been recommended. Specifically, it has been proposed that an expected 1-year survival rate of less than 40% in a re-OLT patient would be an unreasonable use of a donor organ when a primary OLT recipient would be anticipated to have at least double the survival rate. 4 These arguments are further supported by cost-effectiveness data that indicate re-OLT recipients incur significantly higher costs and have longer hospital stays when compared with primary graft recipients. 24, 28 We recognize that limiting re-OLT to the subset of patients expected to have survival outcomes more comparable with primary OLT and precluding re-OLT for patients with high-risk scores (and higher predicted mortality) would represent shifting to an outcomes-based allocation scheme. Because the pace of liver decompensation and risk of death are considerably greater in patients who have received transplants as compared with patients awaiting primary transplantation, it may be necessary to modify the current system so that patients with allograft failure would receive additional priority points within the current MELD schema, akin to patients with hepatocellular carcinoma. 29 In summary, we have validated and refined models to predict survival following re-OLT. The usefulness of the original UNOS model was confirmed with an international cohort that, in terms of demographic and clinical features, differed significantly from the original cohort. Combined data sets were used to generate new models for non-PNF graft failure that do not rely on UNOS status. Although the ethical and practical implications of different liver allocation schemes are complex and rapidly evolving, we feel that these models can be used as objective adjuncts to clinical judgment. Prospective application of these models seems warranted.
